Vicore Pharma Holding AB (publ) (VICO) - Total Assets
Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) holds total assets worth Skr1.22 Billion SEK (≈ $131.25 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Vicore Pharma Holding AB (publ)'s book value for net asset value and shareholders' equity analysis.
Vicore Pharma Holding AB (publ) - Total Assets Trend (2012–2025)
This chart illustrates how Vicore Pharma Holding AB (publ)'s total assets have evolved over time, based on quarterly financial data.
Vicore Pharma Holding AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Vicore Pharma Holding AB (publ)'s total assets of Skr1.22 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 47.4% |
| Accounts Receivable | Skr13.80 Million | 1.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Vicore Pharma Holding AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Vicore Pharma Holding AB (publ) (VICO) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vicore Pharma Holding AB (publ)'s current assets represent 100.0% of total assets in 2025, an increase from 13.2% in 2012.
- Cash Position: Cash and equivalents constituted 47.4% of total assets in 2025, up from 9.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 41.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Vicore Pharma Holding AB (publ) Competitors by Total Assets
Key competitors of Vicore Pharma Holding AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Vicore Pharma Holding AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.31 | 16.50 | 14.68 |
| Quick Ratio | 10.31 | 16.50 | 14.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr1.10 Billion | Skr1.13 Billion | Skr556.03 Million |
Vicore Pharma Holding AB (publ) - Advanced Valuation Insights
This section examines the relationship between Vicore Pharma Holding AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 1.4% |
| Total Assets | Skr1.22 Billion |
| Market Capitalization | $302.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vicore Pharma Holding AB (publ)'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Vicore Pharma Holding AB (publ)'s assets grew by 1.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Vicore Pharma Holding AB (publ) (2012–2025)
The table below shows the annual total assets of Vicore Pharma Holding AB (publ) from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.22 Billion ≈ $131.25 Million |
+1.37% |
| 2024-12-31 | Skr1.20 Billion ≈ $129.47 Million |
+141.67% |
| 2023-12-31 | Skr497.84 Million ≈ $53.58 Million |
+47.29% |
| 2022-12-31 | Skr338.01 Million ≈ $36.37 Million |
-25.08% |
| 2021-12-31 | Skr451.17 Million ≈ $48.55 Million |
+10.98% |
| 2020-12-31 | Skr406.51 Million ≈ $43.75 Million |
+19.17% |
| 2019-12-31 | Skr341.11 Million ≈ $36.71 Million |
+13.10% |
| 2018-12-31 | Skr301.60 Million ≈ $32.46 Million |
+152.33% |
| 2017-12-31 | Skr119.53 Million ≈ $12.86 Million |
+46.39% |
| 2016-12-31 | Skr81.65 Million ≈ $8.79 Million |
-8.49% |
| 2015-12-31 | Skr89.22 Million ≈ $9.60 Million |
+50.29% |
| 2014-12-31 | Skr59.37 Million ≈ $6.39 Million |
+16.45% |
| 2013-12-31 | Skr50.98 Million ≈ $5.49 Million |
+132878.58% |
| 2012-12-31 | Skr38.34K ≈ $4.13K |
-- |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more